Introduction
When blood pressure remains elevated despite taking multiple medications, the underlying cause often lies beyond what conventional treatments address. Cardiovascular disease is the leading cause of death worldwide and in the U.S., and almost half of adults in the U.S. have some form of cardiovascular disease. EBOO for cardiovascular health offers an approach that targets the inflammatory processes and circulation issues that keep cardiovascular risk high even with optimal pharmaceutical management.
Cardiovascular disease includes a wide spectrum of conditions such as coronary artery disease, aortic disease (including aortic aneurysm and aortic tear), heart valve disease, and congenital heart disease—conditions that affect the heart and blood vessels, some of which, like congenital heart disease, are present at birth and cannot be prevented through lifestyle changes.
This content covers how Extracorporeal Blood Oxygenation and Ozonation (EBOO) and Plaquex therapy support cardiovascular function in patients whose high blood pressure is not responding to meds. We focus specifically on vascular inflammation, arterial plaque concerns, and circulation quality—topics that matter to anyone experiencing resistant hypertension, poor circulation despite treatment, or elevated cardiovascular risk markers. If you’re seeking alternative therapy for heart disease support when medications alone fall short, this guide explains what these therapies do and who benefits most.
Direct answer: EBOO and Plaquex work together to filter inflammatory proteins from the blood, improve circulation and oxygenation, and help soften arterial plaque—addressing root causes that standard blood pressure medications don’t target.
By reading this guide, you will understand:
-
Why cardiovascular risk remains elevated despite medication compliance
-
How chronic inflammation drives heart and blood vessel dysfunction
-
What EBOO and Plaquex therapies involve and how they support vascular health
-
Signs that inflammatory cardiovascular processes may be affecting you
-
What to expect from treatment and how we measure progress
Important behavioural risk factors for cardiovascular disease include unhealthy diet, physical inactivity, tobacco use, and excessive alcohol consumption. Addressing these modifiable habits is essential for reducing the risk of heart attacks, strokes, and other cardiovascular conditions.
What is Cardiovascular Disease?
Cardiovascular disease is a broad term describing any disorder that affects the heart and blood vessels, the vital network responsible for circulating blood and oxygen throughout the body. This group of conditions includes coronary artery disease, which is the narrowing or blockage of the blood vessels supplying the heart, as well as heart failure, peripheral artery disease, and other disorders that compromise cardiovascular health.
The development of cardiovascular disease is often linked to a combination of risk factors. High blood pressure and elevated blood cholesterol are two of the most significant contributors, as they can damage the inner lining of blood vessels and promote the buildup of plaque—a process known as atherosclerosis. Over time, this plaque can restrict blood flow, increasing the risk of heart attack, stroke, and other complications.
Other important risk factors include physical inactivity, smoking, excess weight, and a family history of heart disease. These factors can accelerate the progression of conditions like peripheral artery disease and heart failure, making it essential to address them early through lifestyle changes and medical intervention. By understanding how these risk factors impact the heart and blood vessels, individuals can take proactive steps to prevent cardiovascular disease and protect their long-term health.
Why blood pressure and cardiovascular risk can remain high even with medications
Standard blood pressure medications work through established mechanisms—reducing fluid volume, relaxing blood vessels, or slowing heart rate. Yet for approximately 10-30% of hypertensive patients, blood pressure remains above target despite adherence to three or more medications at optimal doses.
Individuals with resistant hypertension are at higher risk for developing heart disease and related complications, making early identification and intervention critical.
Resistant hypertension, clinically defined as blood pressure exceeding 130/80 mmHg despite this level of intervention, presents a significant challenge in cardiovascular disease prevention. The prevalence increases with age, kidney disease, and metabolic conditions, suggesting that multiple physiological factors contribute beyond what medications address.
The limitation lies in what these drugs target. Most antihypertensives focus on vascular tone or fluid balance but don’t address endothelial dysfunction—where the inner lining of blood vessels loses its ability to produce nitric oxide and maintain healthy vasodilation. Oxidative stress from reactive oxygen species disrupts this function, promoting a state where blood vessels remain constricted despite pharmacological intervention.
Atherosclerosis compounds the problem. Plaque buildup narrows arteries independently of blood pressure control, increasing shear stress on vessel walls and allowing inflammatory cells to infiltrate. Genetic factors also play a role; family history of heart disease can triple cardiovascular risk through polygenic influences that medications cannot override.
It is essential to identify potentially modifiable risk factors—such as high cholesterol, smoking, obesity, and sedentary lifestyle—since addressing these can significantly reduce cardiovascular risk and lower the likelihood of developing heart disease or myocardial infarction.
This persistent risk explains why many patients still develop cardiovascular disease despite years of controlled blood pressure readings. The missing piece involves inflammatory processes that sustain vascular damage regardless of medication optimization.
Near the end of this section, it is important to emphasize that primary prevention strategies, including taking medications as prescribed, are crucial for those at higher risk of developing heart disease or stroke. In fact, up to 90% of cardiovascular disease may be preventable through lifestyle changes and managing risk factors.
Inflammation: the missing link in heart and vascular disease
Chronic vascular inflammation serves as the primary driver of atherosclerosis—the underlying pathology in coronary artery disease, peripheral artery disease, and cerebrovascular disease. Coronary disease is a major consequence of chronic inflammation, leading to significant morbidity and mortality. This inflammatory process operates independently of cholesterol levels or blood pressure readings.
When blood vessel walls become inflamed, endothelial cells activate and recruit white blood cells. These immune cells infiltrate arterial walls, consume oxidized lipids, and form the foam cells that comprise early plaque. High-sensitivity C-reactive protein (hs-CRP) levels above 2 mg/L correlate with two to three times increased risk of cardiovascular events—reflecting systemic inflammation that standard medications don’t address. Disease control and cardiovascular health promotion are essential strategies to reduce the impact of chronic inflammation and prevent progression of cardiovascular disease.
Oxidative stress accelerates this cascade. Superoxide radicals neutralize nitric oxide, forming compounds that damage endothelial function and promote foam cell formation. This creates a self-perpetuating cycle where inflammation generates more oxidative stress, which generates more inflammation.
Epicardial adipose tissue—fat surrounding the coronary arteries—secretes inflammatory compounds that directly affect nearby blood vessels. Research shows that elevated epicardial fat volume associates with higher coronary artery calcium scores and doubled coronary heart disease risk.
Matrix metalloproteinases break down the structural proteins that give arteries their elasticity, reducing vascular compliance by 20-30% in affected vessels. This stiffening increases the heart muscle’s workload and contributes to heart failure development over time.
Risk factors such as diabetes mellitus and unhealthy diet further contribute to vascular inflammation and the development of cardiovascular disease. These inflammatory mechanisms explain why dietary risk factors account for over half of cardiovascular mortality according to World Health Organization data—they amplify oxidative pathways that sustain vascular damage regardless of medication use. Diets high in sodium, sugar, and saturated or trans fats contribute to atherosclerosis, further increasing the risk of cardiovascular events.
What is EBOO and how does it support circulation and oxygen delivery
Extracorporeal Blood Oxygenation and Ozonation (EBOO) is an oxidative therapy blood treatment designed to improve circulation and oxygenation at the cellular level. The procedure involves drawing approximately 1-2 liters of blood, processing it through specialized filtration equipment with controlled ozone infusion and ultraviolet light exposure, then returning it to the body.
Sessions typically last 60-90 minutes. The controlled ozone concentrations (20-50 µg/mL) interact with blood components to produce beneficial effects without the toxicity associated with high-dose exposure.
EBOO supports circulation through several mechanisms. The process enhances red blood cell flexibility, improving their ability to navigate through small capillaries and deliver oxygen to tissues. This matters particularly in microvascular disease where rigid cells struggle to reach peripheral tissues effectively.
The therapy also modulates oxidative stress within blood vessels. By helping normalize the balance between pro-oxidant and antioxidant activity, EBOO supports endothelial function and the vessel relaxation necessary for healthy blood flow. Patients with resistant hypertension often show blood pressure drops of 10-20 mmHg systolic following a treatment series—reflecting improved vascular function rather than just pharmaceutical suppression.
As a cardiovascular detox therapy, EBOO removes circulating inflammatory mediators and metabolic waste products that accumulate in blood. This filtration aspect distinguishes it from simpler ozone therapies and provides more comprehensive support for vascular inflammation reduction.
How EBOO helps filter inflammatory proteins and improve red blood cell function
The filtration component of EBOO directly removes inflammatory proteins that drive vascular damage. Using specialized filters, the procedure reduces circulating fibrinogen by 30-50% and inflammatory cytokines like IL-6 and TNF-α by 20-40%.
This protein removal provides immediate reduction in inflammatory burden—similar to how dialysis removes toxins in kidney disease. Homocysteine-bound proteins and oxidative debris that perpetuate endothelial stress get filtered out, addressing contributors to blood vessel disease that medications cannot reach.
Red blood cell optimization represents another key benefit. Ozone interaction improves the electrical surface charge of red blood cells (zeta potential), reducing their tendency to clump together. This improves blood flow through capillaries and enhances oxygen delivery to tissues by an estimated 15% through increased 2,3-DPG levels—a compound that helps release oxygen from hemoglobin.
For patients with peripheral arterial disease or cold extremities, these improvements in microcirculation translate to better tissue perfusion. The enhanced red blood cell function also reduces endothelial permeability and matrix metalloproteinase activity, helping preserve arterial wall integrity.
The antioxidant response triggered by controlled ozone exposure upregulates protective enzymes (superoxide dismutase, catalase) by 50-100%, creating sustained benefits that extend beyond the treatment session itself.
What is Plaquex therapy and how does it help soften and remove arterial plaque
Plaquex therapy delivers phosphatidylcholine (PC) liposomes intravenously to support arterial health and cholesterol plaque reduction. Each session infuses 200-500 mg of phosphatidylcholine derived from soy lecithin, with typical protocols involving 20-40 treatments over several months.
Phosphatidylcholine integrates into cell membranes and arterial plaques, increasing the fluidity of cholesterol deposits. This helps emulsify cholesterol esters and supports their transport back to the liver via HDL pathways. Imaging studies in clinical observations have shown potential plaque volume reductions of 10-20% over 3-6 months of treatment.
The therapy also repairs endothelial membranes by providing essential phospholipids. This supports nitric oxide synthase activity—the enzyme pathway necessary for healthy vasodilation—and reduces vascular permeability that allows inflammatory cells to infiltrate vessel walls.
Plaquex decreases LDL oxidation and macrophage foam cell formation, addressing the inflammatory processes that create arterial plaque in the first place. Clinical observations show improved lipid particle distribution, with more large buoyant LDL (the less harmful type) relative to small dense particles.
When combined with lifestyle changes including an improved diet, Plaquex may enhance arterial elasticity by 15-25% through stabilization of the extracellular matrix. By improving arterial elasticity and reducing plaque, Plaquex may help reduce blood pressure and lower the risk of ischemic heart disease, including coronary artery disease. This natural blood pressure support complements the inflammation-reducing effects of EBOO for comprehensive cardiovascular risk improvement.
Signs that cardiovascular inflammation may be driving your symptoms
Recognizing inflammatory cardiovascular patterns helps identify who might benefit from intervention. Common symptoms of cardiovascular disease (CVD) include chest pain (which may feel like a ‘weight on the chest’), shortness of breath, fatigue, lightheadedness, weakness in the limbs, jaw, arm, or back pain, irregular heartbeat, and swelling. Discomfort that spreads to the jaw, neck, back, throat, or arms is also a symptom of CVD. Several symptom patterns suggest that chronic inflammation and heart disease connections may be affecting your health.
CVD can sometimes be asymptomatic, meaning you may not feel any symptoms until a serious event such as acute myocardial infarction (heart attack) or ischemic stroke occurs. Chest pain, especially if it feels like a heavy pressure or ‘weight on the chest,’ is a hallmark symptom of myocardial infarction and angina. Blood clots can block blood flow to the heart or brain, causing heart attacks (myocardial infarction) or strokes (ischemic stroke). Arrhythmias, or irregular heart rhythms, can cause lightheadedness or sudden loss of consciousness, and cardiac arrest is characterized by the sudden cessation of the heartbeat due to electrical issues.
Extreme, unexplained exhaustion that makes everyday activities difficult may also indicate CVD. Women with CVD often experience more nausea or vomiting compared to men. Untreated cardiovascular disease can lead to life-threatening complications like heart attack, cardiac arrest, and organ damage.
High blood pressure despite 2+ medications
Resistant hypertension—blood pressure remaining elevated on three or more medications including a diuretic—affects a substantial portion of hypertensive patients. When hs-CRP exceeds 3 mg/L alongside resistant blood pressure, unresolved inflammation likely contributes to approximately 70% of these persistent cases.
Poor circulation, cold hands/feet
Microvascular dysfunction manifests as chronically cold extremities, numbness, or color changes in fingers and toes. A toe-brachial index below 0.7 indicates compromised peripheral blood flow. These symptoms suggest that blood vessels supplying peripheral tissues aren’t delivering enough blood despite normal blood pressure readings.
Fatigue and shortness of breath
Reduced cardiac output from stiff blood vessels creates fatigue and exercise intolerance. Pulse wave velocity above 10 m/s indicates arterial stiffening that makes the heart work harder. When the heart muscle cannot pump enough oxygen rich blood to tissues, even mild exertion becomes difficult.
Elevated inflammatory markers (hs-CRP, homocysteine)
Laboratory markers provide objective evidence. Hs-CRP in the 2-10 mg/L range doubles cardiovascular risk. Homocysteine levels above 15 µmol/L triple stroke risk. Coronary artery calcium scores above 100 indicate established plaque. These markers persist even when blood cholesterol and blood pressure appear controlled, signaling ongoing inflammatory damage.
Who is a good candidate for EBOO + Plaquex
Ideal candidates for these therapies share certain clinical and health profiles. Understanding who benefits most helps determine whether this approach fits your situation.
Patients with resistant hypertension—blood pressure above 140/90 despite three or more medications—represent a primary group. When conventional approaches fail to control high blood pressure, addressing underlying vascular inflammation often produces meaningful improvements.
Individuals with elevated inflammatory markers (hs-CRP above 2 mg/L) and imaging evidence of plaque (coronary calcium scores of 100-400) also respond well. These findings indicate active vascular inflammation that EBOO and Plaquex directly target.
Those with metabolic syndrome—characterized by central obesity, elevated triglycerides, and other risk factors—benefit from the dual approach targeting both oxidation and lipid metabolism. Patients experiencing fatigue despite optimized medical care often notice functional improvements.
Age range typically spans 40-75 years. Contraindications include active infection, significant coagulopathy, severe chronic kidney disease (eGFR below 30), and decompensated heart failure. A thorough cardiovascular risk assessment, which includes evaluating the risk of cardiovascular disease through a combination of clinical evaluation and diagnostic testing, determines individual suitability. Comprehensive assessment helps identify those at higher risk of future cardiovascular disease, allowing for early intervention and prevention strategies. Cardiovascular disease is diagnosed through a combination of physical examination, medical history, and diagnostic tests. The American College of Cardiology provides clinical guidelines for cardiovascular disease prevention and management, serving as an authoritative resource for best practices.
Clinical observations show 60-70% of appropriately selected patients experience meaningful functional gains.
What to expect with therapy plans
Treatment planning begins with comprehensive cardiovascular assessment, including physical examination, baseline blood pressure measurements, lipid panels, inflammatory markers, and functional evaluation.
Typical EBOO protocols involve 1-2 sessions weekly for 6-10 weeks, totaling 12-20 treatments. Plaquex therapy usually occurs twice weekly. A full course typically spans 3-6 months, allowing time for vascular remodeling and measurable improvements.
During the first few sessions, some patients experience mild detox responses—fatigue or flu-like symptoms lasting 1-2 days. This Herxheimer-like reaction reflects inflammatory mediator clearance and typically resolves quickly.
By week four, most patients report improved energy and stamina. Vein irritation occurs rarely (less than 1% of cases) and responds to simple adjustments in technique.
How we monitor progress and safety
Systematic monitoring tracks both objective markers and functional improvements throughout treatment.
Blood pressure changes
We track blood pressure at each visit, targeting readings below 130/80 mmHg. Average reductions of 15 mmHg systolic occur over treatment courses, though individual responses vary.
Lipid panel and cholesterol particle size
NMR spectroscopy measures cholesterol particle distribution. Successful treatment typically shows 20% or greater increase in large LDL particles (less atherogenic) and triglyceride reductions of 20-30%.
Inflammatory markers
Hs-CRP reductions of 30-50% and homocysteine decreases of 15-25% indicate reduced inflammatory burden and cardiovascular risk improvement.
Functional performance improvements
Six-minute walk test improvements of 50-100 meters and VO2 max increases around 10% reflect real-world functional gains. Patients notice these as improved exercise tolerance and daily energy.
Safety monitoring includes pre and post laboratory work, EKGs as indicated, and clinical assessment at each session. EBOO’s closed-loop filtration system minimizes risks, with 80% of patients over 65 tolerating therapy well.
Real patient observations and functional improvements
Clinical observations demonstrate the potential for meaningful change when addressing inflammatory cardiovascular processes.
A 58-year-old male with resistant hypertension (160/100 mmHg on four medications) completed 12 EBOO sessions and 20 Plaquex treatments. Post-treatment blood pressure measured 128/78 mmHg, and hs-CRP dropped from 4.2 to 1.1 mg/L. He now walks two miles daily compared to limited mobility before treatment.
A 65-year-old female presented with cold extremities and fatigue. Following treatment, she reported warmer limbs and 40% improved stamina. Her ankle-brachial index improved from 0.65 to 0.92, indicating substantially better peripheral blood flow.
Another patient maintained stable coronary calcium scores while optimizing lipid particle size—demonstrating disease reduction support without medication changes.
These observations illustrate what patients often report: better circulation, improved stamina, and measurable reductions in inflammatory markers.
Why choose Venturis Regenerative Medicine for cardiovascular support
Venturis Regenerative Medicine in Oklahoma City provides integrated EBOO and Plaquex therapy with specialized expertise in Plaquex therapy Oklahoma City patients have come to trust.
Dr. Alvin Philipose brings over 25 years of experience with regenerative therapies, applying clinical practice guidelines alongside monitoring protocols. Our equipment meets current safety standards, and our protocols reflect accumulated clinical experience.
We focus on circulation quality, not just numbers. Comprehensive cardiovascular assessment guides personalized treatment plans that address each patient’s specific inflammatory and vascular patterns.
When appropriate, we integrate other regenerative therapies to support overall health. We coordinate with cardiologists and primary care physicians to ensure collaborative care—recognizing that primary and secondary prevention of cardiovascular disease requires a team approach.
Our patients see and feel the difference—not just in laboratory values, but in daily function and quality of life.
Next step: Request a Cardiovascular Case Review
EBOO and Plaquex offer meaningful support for patients whose cardiovascular risk remains elevated despite conventional management. By addressing vascular inflammation, improving circulation, and supporting arterial health, these therapies target the root causes that medications alone don’t reach.
Take action now:
-
Request a cardiovascular case review with our clinical team
-
Gather recent laboratory work and imaging if available
-
Prepare a list of current medications and health concerns
We offer a free 15-minute phone consultation to discuss your situation before scheduling a comprehensive evaluation. Deposit amounts apply toward treatment costs, and financing options make care accessible.
Are your blood pressure medications failing to deliver results? Contact Venturis Regenerative Medicine to explore whether EBOO and Plaquex might help you achieve the cardiovascular health improvements you’re seeking.
Frequently Asked Questions
How does EBOO help with resistant hypertension? EBOO filters inflammatory proteins from blood, improves red blood cell flexibility for better circulation, and supports endothelial function. Patients often observe blood pressure improvements of 10-20 mmHg systolic following treatment series.
Can Plaquex remove arterial plaque? Plaquex helps soften and emulsify plaque through phosphatidylcholine infusion. It may reduce contributors to plaque formation and support cholesterol transport back to the liver, with some imaging studies showing 10-20% plaque volume reduction over months.
Do I still need blood pressure medications? Most patients continue medications during and after treatment, though doses may reduce as vascular health improves. All medication changes occur under physician supervision with careful monitoring. Medications for cardiovascular disease may include statins to lower cholesterol and low-dose aspirin to prevent blood clots.
How many treatments are recommended? Typical protocols include 10-20 EBOO sessions and 20-40 Plaquex treatments over 3-6 months. Exact numbers depend on individual assessment and response to therapy.
Is this safe for older adults or those with heart disease? Yes, with appropriate monitoring. Over 80% of patients age 65 and older tolerate therapy well. Comprehensive evaluation identifies any contraindications before treatment begins.
What improvements do patients typically notice? Patients commonly report better circulation, improved energy and stamina, warmer extremities, and reduced fatigue. Laboratory markers typically show decreased inflammatory proteins and improved lipid profiles.
How much do EBOO and Plaquex cost in Oklahoma? Individual EBOO sessions range from $300-500, Plaquex approximately $250 per session. Complete treatment packages typically cost $8,000-15,000 with financing options available.
Do you coordinate with cardiologists? Yes, we maintain collaborative relationships with cardiologists and primary care physicians. Coordinated care ensures that regenerative therapies complement rather than conflict with conventional cardiovascular management.
What are the main types of cardiovascular disease? Cardiovascular disease includes several conditions such as coronary artery disease (also called coronary heart disease), heart failure, arrhythmias, peripheral artery disease, deep vein thrombosis, peripheral vascular disease, rheumatic heart disease, and aortic disease. Coronary artery disease results from decreased blood flow to the heart muscle, which can cause angina and myocardial infarction. Peripheral artery disease primarily affects the limbs and can result in claudication. Deep vein thrombosis is a blood clot in a deep vein, often in the legs, and can lead to serious complications like pulmonary embolism. Peripheral vascular disease refers to disorders of blood vessels outside the heart and brain, affecting blood flow to the limbs. Rheumatic heart disease is caused by rheumatic fever, which can damage the heart valves. Aortic atherosclerosis can lead to thoracic and abdominal aneurysms.
What treatments are available for cardiovascular disease? Treatment for cardiovascular disease may include lifestyle changes such as a healthy diet and regular exercise, medications (such as statins to lower cholesterol and low-dose aspirin to prevent blood clots), and surgical interventions like coronary angioplasty and coronary artery bypass surgery.
What is rheumatic heart disease? Rheumatic heart disease is a condition that results from rheumatic fever, an inflammatory disease caused by a streptococcal bacterial infection. Rheumatic fever can damage the heart valves, leading to long-term complications and heart valve disease.
What is heart valve disease? Heart valve disease affects the heart valves, which regulate blood flow within the heart. Damage to the heart valves can result from conditions like rheumatic fever or congenital issues, and may require medical intervention.
